In the News
Russo Partners works at the intersection of science, medicine, and media. The stories below reflect the conversations we help shape covering breakthroughs in biopharma, digital health, healthcare, and beyond.
Citeline In Vivo
|
September 28, 2026
Strategic Intent: Boehringer Ingelheim’s Brian Hilberdink on Launching Into the GLP-1 Era
Boehringer Ingelheim’s US Human Pharma president on navigating a major launch cycle, competing in obesity without chasing pounds, and playing…
For more
San Diego Business Journal
|
September 24, 2026
Persephone Bio Synbiotic Giving Good Gut Feeling
Roughly 90% of babies in the U.S. are born without the essential levels of certain gut bacteria that they need…
For more
FOX10
|
September 17, 2026
Arizona researchers pioneer autism urine screening targeting gut bacteria
A breakthrough in autism research in the Valley is offering incredible new hope to families. A Phoenix-based company is looking…
For more
Biotech TV
|
September 15, 2026
HCW 2026: InflaRx designed izicopan from the start with the goal of having a differentiated, best in class profile vs the first marketed C5aR inhibitor. Now more than ever this could be opportune
Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been…
For more
PharmaVoice
|
September 15, 2026
Cocrystal Pharma’s new CEO hopes to crack the norovirus code
James Sapirstein is bringing his Big Pharma chops to the clinical-stage company’s efforts to finally deliver an effective treatment for…
For more
BioTech Nation
|
September 8, 2026
A Different Approach to Treating Gout…Dr. James Mackay, Co-Founder, CEO, & President, Crystalys Therapeutics
On this episode of BioTech Nation…Dr. James Mackay joins to talk about the progress Crystalys Therapeutics is making in the…
For more
GEN News
|
August 27, 2026
Aprea Expands Development of WEE1 Inhibitor After Seeing Early Clinical Activity Signs vs. Cancer
Aprea Therapeutics is accelerating enrollment in its ongoing Phase I trial of its targeted cancer therapy APR-1051, one of the…
For more
GEN News
|
August 12, 2026
Next 10 U.S. Biopharma Clusters
For the first time, GEN examines the top regions and top states just below the 10 largest regions for life…
For more
Clarivate
|
August 5, 2026
7 weight loss companies to watch: innovators in GLP-1s and beyond
The market for weight loss treatments is a crowded one, and new entrants are piling in. The latest in our…
For more
Pulse 2.0
|
August 5, 2026
Ratio Therapeutics Raises $70 Million Series C To Advance Radiopharmaceutical Pipeline
Ratio Therapeutics has raised $70 million in Series C funding to advance its targeted radiopharmaceutical pipeline and expand its manufacturing…
For more
Upcoming Events
Our team is active across the industry year-round. Find us at these upcoming conferences and events.
